Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Immunology

The Molecular Map: How AOID Disarms the Immune System

At a Glance

Adult-onset immunodeficiency (AOID) occurs when the body produces autoantibodies that block interferon-gamma, preventing immune cells from fighting infections. Diagnosis requires specialized tests like functional neutralizing assays and mNGS to confirm the blockage and identify elusive pathogens.

Understanding the biology of Adult-Onset Immunodeficiency (AOID) helps turn a confusing diagnosis into a clear roadmap for treatment. At its core, this condition is a communication failure between your immune cells.

The Biological “Short Circuit”

To fight off certain germs, your immune system relies on a “kill signal” called interferon-gamma (IFN-γ) [1]. Under normal circumstances, this protein acts like a key that fits into a lock on your immune cells (macrophages). When the key turns, it activates a pathway inside the cell called JAK-STAT1 [2]. This pathway tells the macrophage to become aggressive and destroy pathogens hiding inside it [3].

In AOID, your body mistakenly creates autoantibodies—proteins that act like “gum” in the lock. They stick to the IFN-γ before it can reach the cell [4]. This blocks the STAT1 phosphorylation (the “turning of the key”), leaving your macrophages unable to fight off specific invaders like mycobacteria or fungi [5][6].

The Genetic Link (HLA)

Researchers have found that many people with this condition share specific genetic markers known as Human Leukocyte Antigen (HLA) alleles [7]. HLA genes help your immune system distinguish between “self” and “foreign” invaders. In many AOID patients—especially those of Southeast Asian descent—the presence of HLA-DRB1*16:02 and HLA-DQB1*05:02 is strongly linked to the production of these autoantibodies [8][9].

The Diagnostic Process

Diagnosing AOID requires a multi-step approach to move from “suspicion” to “confirmation.”

  • Step 1: ELISA (Screening): This is a standard lab test used to detect the presence and quantity (titer) of the anti-IFN-γ autoantibodies in your blood [10][11].
  • Step 2: Functional Neutralizing Assays (Confirmation): Simply having the antibodies isn’t enough; doctors must prove they are active. This test checks if your serum actually blocks STAT1 phosphorylation in a laboratory setting [10]. If the pathway is blocked, the antibodies are confirmed to be “neutralizing.”
  • Step 3: mNGS (Pathogen Identification): Because the germs in AOID can be very difficult to grow in traditional cultures, doctors may use Metagenomic Next-Generation Sequencing (mNGS) [12]. This advanced tool scans all the DNA and RNA in a sample to quickly identify “elusive” pathogens that standard tests might miss [13].

Your Lab Report Checklist

When reviewing your records, look for these specific terms to ensure a complete evaluation:

  • Anti-IFN-γ Antibody Titer: Indicates the concentration of autoantibodies [10].
  • STAT1 Phosphorylation Inhibition: Confirms the antibodies are blocking the immune signal [2].
  • HLA Genotype: Specifically looking for the DRB1 and DQB1 markers [7].
  • mNGS Results: Lists any DNA/RNA of bacteria, fungi, or viruses found in your samples [12].

By identifying exactly where the “short circuit” is occurring, your medical team can target the autoantibodies directly, often using treatments like rituximab to stop the cells from making them in the first place [14][9].

Common questions in this guide

What does a functional neutralization assay test for in AOID?
This specialized lab test confirms whether your autoantibodies are actively blocking the JAK-STAT1 immune pathway. It proves that the antibodies are neutralizing your immune system's ability to fight infections.
What does my anti-IFN-gamma antibody titer mean?
The titer indicates the concentration or level of autoantibodies in your blood. Doctors monitor this number over time to see how severe the blockage is and whether treatments are effectively reducing the antibodies.
Why might my doctor order an mNGS test?
Metagenomic Next-Generation Sequencing (mNGS) is an advanced test used when standard cultures fail to grow the germs causing your illness. It scans DNA and RNA to quickly identify elusive bacteria or fungi hidden in your body.
What role do HLA genes play in adult-onset immunodeficiency?
Certain genetic markers, particularly HLA-DRB1*16:02 and HLA-DQB1*05:02, are strongly linked to the production of anti-IFN-gamma autoantibodies. Testing for these markers helps doctors understand your genetic predisposition to the condition.
How do autoantibodies cause AOID?
In AOID, your body creates autoantibodies that stick to interferon-gamma proteins before they can activate your immune cells. This short circuits your immune response, leaving macrophages unable to destroy specific invading germs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my lab tests include a 'functional neutralization assay' to confirm that my antibodies are blocking the JAK-STAT1 pathway?
  2. 2.What was the 'titer' or level of my anti-IFN-gamma autoantibodies, and how will we monitor this over time?
  3. 3.Should we perform HLA testing for the DRB1*16:02 and DQB1*05:02 alleles to better understand my genetic predisposition?
  4. 4.If my standard cultures are negative, can we use mNGS (metagenomic sequencing) on a blood or tissue sample to find the specific germ causing my symptoms?
  5. 5.How does the 'STAT1 phosphorylation' result affect our decision to use immunotherapies like rituximab?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Blockade Effects of Anti-Interferon- (IFN-) γ Autoantibodies on IFN-γ-Regulated Antimicrobial Immunity.

    Krisnawati DI, Liu YC, Lee YJ, et al.

    Journal of immunology research 2019; (2019()):1629258 doi:10.1155/2019/1629258.

    PMID: 31275997
  2. 2

    Disseminated tuberculosis, CMV viraemia & haemophagocytic-lymphohistiocystosis syndrome in an adult patient with anti- IFNγ autoantibodies - case report and brief review.

    Butel-Simoes GI, Kiss C, Kong K, et al.

    Clinical immunology communications 2023; (4()):55-59 doi:10.1016/j.clicom.2023.08.001.

    PMID: 37906631
  3. 3

    Anti-Interferon-γ Autoantibodies Impair T-Lymphocyte Responses in Patients with Talaromyces marneffei Infections.

    Chen ZM, Yang XY, Li ZT, et al.

    Infection and drug resistance 2022; (15()):3381-3393 doi:10.2147/IDR.S364388.

    PMID: 35789796
  4. 4

    Neutralizing Activity of Anti-interferon-γ Autoantibodies in Adult-Onset Immunodeficiency Is Associated With Their Binding Domains.

    Yasamut U, Thongkum W, Moonmuang S, et al.

    Frontiers in immunology 2019; (10()):1905 doi:10.3389/fimmu.2019.01905.

    PMID: 31474987
  5. 5

    Anti-interferon-γ autoantibody syndrome mimicking lymphoproliferative disorders: a case series.

    Ren D, Wee LEI, Lee SSM, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2026; (170()):108860 doi:10.1016/j.ijid.2026.108860.

    PMID: 42269920
  6. 6

    Th1 cell immune response in Talaromyces marneffei infection with anti-interferon-γ autoantibody syndrome.

    Qiu Y, Li Z-T, Zeng W, et al.

    Microbiology spectrum 2024; (12(5)):e0364623 doi:10.1128/spectrum.03646-23.

    PMID: 38497717
  7. 7

    Factors associated with acquired Anti IFN- γ autoantibody in patients with nontuberculous mycobacterial infection.

    Phoompoung P, Ankasekwinai N, Pithukpakorn M, et al.

    PloS one 2017; (12(4)):e0176342 doi:10.1371/journal.pone.0176342.

    PMID: 28437431
  8. 8

    Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections.

    Guo J, Ning XQ, Ding JY, et al.

    The Journal of experimental medicine 2020; (217(12)) doi:10.1084/jem.20190502.

    PMID: 32880631
  9. 9

    Anti-IFN-γ Autoantibody Syndrome Presenting with Disseminated Nontuberculous Mycobacteria Infections: A Case Series of Therapeutic Implications and Review of Literature.

    Cheng B, Bajwa B, Choi S, et al.

    Tropical medicine and infectious disease 2025; (10(7)) doi:10.3390/tropicalmed10070202.

    PMID: 40711078
  10. 10

    The impact of neutralizing anti-IFN-γ autoantibodies on GBP5 expression and monocyte dysfunction in adult-onset immunodeficiency.

    Sornsuwan K, Juntit OA, Thongheang K, et al.

    Immunobiology 2025; (230(6)):153134 doi:10.1016/j.imbio.2025.153134.

    PMID: 41187578
  11. 11

    Latticed Gold Nanoparticle Conjugation via Monomeric Streptavidin in Lateral Flow Assay for Detection of Autoantibody to Interferon-Gamma.

    Thongkum W, Yasamut U, Chupradit K, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(6)) doi:10.3390/diagnostics11060987.

    PMID: 34072539
  12. 12

    Disseminated Talaromyces marneffei infection mimicking tuberculosis in an HIV-negative adult with anti-IFN-γ autoantibodies: a case report.

    Liu J, Wu J, Zhang W, et al.

    BMC infectious diseases 2025; (26(1)):1 doi:10.1186/s12879-025-12264-9.

    PMID: 41318438
  13. 13

    Disseminated Mycobacterium kansasii disease complicating Talaromyces marneffei infection in patient with anti-IFN-γ autoantibodies: a case report.

    Wei S, Meng D, Qin J, et al.

    BMC infectious diseases 2025; (25(1)):1157 doi:10.1186/s12879-025-11535-9.

    PMID: 41013333
  14. 14

    Rituximab Restores IFN-γ-STAT1 Function and Ameliorates Disseminated Mycobacterium avium Infection in a Patient with Anti-Interferon-γ Autoantibody.

    Koizumi Y, Sakagami T, Nishiyama N, et al.

    Journal of clinical immunology 2017; (37(7)):644-649 doi:10.1007/s10875-017-0425-3.

    PMID: 28779413

This page explains AOID biology and lab terminology for educational purposes only. Always consult your immunologist or infectious disease specialist to interpret your specific test results.

Get notified when new evidence is published on Adult-onset immunodeficiency with anti-interferon-gamma autoantibodies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.